Kornimate/medical-research-clean huggingface dataset:
a multicenter trial comparing multi-course chemotherapy in locoregionally advanced nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: locoregionally advanced nasopharyngeal carcinoma (npc)(stage iii, iv in uicc 2002 classification) can be divided into two groups according to the risk of metastasis: high-risk metastasis group (t4 or n2-3) and low-risk metastasis group (t3n0-1). in low-risk metastasis group, concurrent chemoradiotherapy (ccrt) might decrease local recurrence and distance metastasis, which benefits overall survival. on the other hand, neoadjuvant chemotherapy is also associated with lower distance metastasis of advanced stage npc. nevertheless, ccrt alone or neoadjuvant chemotherapy alone leads to unsatisfactory results regarding to distance metastasis in patients with high-risk metastasis group. in this case, it is utmost important to investigate the new treatment combining neoadjuvant chemotherapy plus ccrt in order to improve overall survival of locoregionally advanced npc with high-risk metastasis. in our study, in order to investigate the effect and adverse reaction of neoadjuvant chemotherapy plus ccrt on distance metastasis and locoregionally relapse, four hundred patients with high risk of distance metastasis will be randomly divided into two groups, comparing neoadjuvant chemotherapy (ddp+5fu) plus ccrt (ddp) and ccrt (ddp) alone. we aim to find out the best therapeutic regimen with lowest adverse reaction for npcs with high risk of distance metastasis.


Eligibility criteria:
inclusion criteria: * patients with newly histologically confirmed nasopharyngeal carcinoma, including who ii or iii * original clinical stage must be t4 or n2-3 （uicc 2002） * male and no pregnant female * age between 18-60 * wbc ≥4,000/mm3 and plt ≥ 100,000/mm3 * with normal liver function test (alt、ast≤2.5×uln) * with normal renal function test (creatinine ≤ 1.5×uln) * performance status scale ecog grade 0，1 * without radiotherapy or chemotherapy * patients must give signed informed consent exclusion criteria: * patients have evidence of relapse or distant metastasis * the presence of uncontrolled life-threatening illness * receiving other ways of anti-cancer therapy * receiving radiotherapy or chemotherapy * investigator consider the patients can't finish the whole study

Keywords: nasopharyngeal carcinoma neoadjuvant chemotherapy concurrent chemotherapy randomized controlled clinical trials
etiology and outcomes of tropical acute respiratory distress syndrome

Conditions: Acute Respiratory Distress Syndrome

Summary: this is a prospective observational study done to know the etiology and outcomes of acute respiratory distress syndrome.

the study will be a prospective observational study and 64 patients with ards will be recruited . written informed consent will be taken prior to inclusion of study. study will be conducted in medical icu (c2 icu) of aiims. based on medical history and physical examination, radiology, biochemical and microbiological investigations etiology of ards will be decided.sample will be taken at te eime of admission for estimation of inflammatory markers hscrp,il-1.il-6,tnf ,procalcitonin.from the available variables apache ii, sequential organ failure assessment score (sofa), simplified acute physiological score (saps)ii and 3 will be calculated to assess the severity of ards.all patients will be given mechanical ventilation using the protocol followed by the ards network low-tidal volume ventilation strategy.the data will be registered on icu admission and there after every 24 hr. day 0 will be defined as the interval from the time of icu admission to 8:00 am the next day .every day data will be recorded at a fixed time at 9 am. it will include tidal volume vt (ml/kg),respiratory rate/min, minute ventilation(l/min),fio2,pao2/fio2,inspiratory flow(i:e), ppeak (cm of h2o),static respiratory compliance(ml/cm of water).plateau pressure (pplat), peak end expiratory pressure (peep).patient will be monitored throughout the course of illness and the outcome of ards will be assessed.

Eligibility criteria:
inclusion criteria: 1. subjects fulfilling the criteria of ards according to american-european consensus definition 2. admitted in medical icu(cii/cu) 3. no known previous lung pathology e.g. bronchiectasis, interstitial lung disease exclusion criteria: 1. hiv positive serology. 2. chronic obstructive airway disease 3. not giving consent for study 4. known lung pathology

Keywords: etiology and outcomes of ards
primary eosinophilic colitis in symptomatic patients.

Conditions: Eosinophilic Colitis

Summary: the aim of the present study was to know the prevalence of primary eosinophilic colitis(pec) in patients with lower gastrointestinal symptoms including diarrhea and chronic abdominal pain for which no other causes were identified.

the presence of eosinophils in the different segments of the digestive tract is common and seen in diverse clinical scenarios. eosinophilic gastrointestinal diseases (egids) are a group of disorders characterized by symptoms of gastrointestinal dysfunction, caused by the inflammatory infiltration of eosinophils and include eosinophilic esophagi-tis, eosinophilic gastroenteritis, and eosinophilic colitis. primary eosinophilic colitis (pec) is defined as an inflammatory disease of unknown etiology that mainly manifests as abdominal pain and diarrhea, segmental or diffuse infiltration of eosinophils in the mucosa of the colon, for which other possible causes have been ruled out . the usual endoscopic findings tend to be nonspecific, and even though pec is considered a rare disease, its prevalence is unknown. evaluation of the colonic mucosa is very helpful in detecting inflammatory bowel disease, ischemic colitis, microscopic colitis ,neoplasia, and intraepithelial infections. the endoscopic appearance of the colon is normal, or almost normal, in some of those diseases, and thus they can go by undetected

Eligibility criteria:
inclusion criteria: * all in- patients and out- patients above 18 y old undergo colonoscopy unit in al raghy hospital with unexplained lower symptoms including abdominal pain ,diarrhea, ibs predominant diarrhea, between , between february 2023 and december 2024 and exclusion criteria: * cases diagnosed with 2ry causes for colonic eosinophilia. * patients with a known or compensated organic disease associated with diarrhea and alarm features (e.g., involuntary weight loss \> 10% of the baseline weight, within the past 6 months. * patients with anemia, cancer and history of organ transplantation. * patients with hiv-aids infection. * patients under regular treatment with clozapine, carba-mazepine, rifampin, tacrolimus, gold salts, or non steroidal anti-inflammatory drugs, for 6 months prior to disease onset. * patients contraindicated for colonoscopy or biopsy, and patients with incomplete colonoscopy or inadequate bowel cleanliness at the time of the study .
a study of arry-614 in patients with low or intermediate-1 risk myelodysplastic syndrome

Conditions: Myelodysplastic Syndromes

Summary: this is a phase 1 study during which patients with low or intermediate-1 risk myelodysplastic syndrome (mds) will receive investigational study drug arry-614. this study has 2 parts. in the first part, patients will receive increasing doses of study drug, given either with food or without food, in order to achieve the highest dose of the study drug possible that will not cause unacceptable side effects. approximately 60 patients from the us will be enrolled in part 1 (completed). in the second part of this study, patients will receive the best dose of study drug, given either with food or without food, determined from the first part of the study and will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. approximately 40 patients from the us will be enrolled in part 2 (completed).


Eligibility criteria:
key inclusion criteria (part 1 and part 2): * diagnosis of mds by bone marrow biopsy. * international prognostic scoring system (ipss) score of low or intermediate-1 risk mds. * may have received prior therapy for mds. * eastern cooperative oncology group (ecog) performance status (ps) between 0 and 2. * adequate liver and renal function. * additional criteria exist. key exclusion criteria (part 1 and part 2): * history of bone marrow transplant. * concomitant malignancies or previous malignancies with less than a 2-year disease-free interval at the time of enrollment. * treatment with an investigational medicinal product that is not expected to be cleared by the first dose of study drug or that has demonstrated to have late side effects. * known positive serology for the human immunodeficiency virus (hiv), hepatitis c and/or active hepatitis b. * additional criteria exist.

Keywords: low or intermediate-1 risk myelodysplastic syndrome
apnoeic oxygenation by nasal cannula during airway management in children undergoing general anaesthesia.

Conditions: Apnoeic Oxygenation

Summary: airway management is a core clinical skill in anaesthesia. pre-oxygenation prior to induction of anaesthesia is standard practice to prevent desaturation. apnoeic oxygenation in adults is effective and prolongs the time to desaturation. the effectiveness of apnoeic oxygenation in the adult is well document, however evidence in the paediatric is lacking. therefore, the aim of this study was to investigate the effectiveness of apnoeic oxygenation during airway management in children. this was a pilot randomised controlled trial. patients were randomised to either receive apnoeic oxygenation or standard care during the induction of anaesthesia. the primary outcome was the duration of safe apnoea, defined as a composite of the time to first event, either time for spo2 to drop to 92% or time to successfully secure the airway, and the lowest spo2 observed during airway management. secondary outcomes were number of patients whose spo2 dropped below 95% and number of patients whose spo2 dropped below 92%.


Eligibility criteria:
inclusion criteria: * patients were included who were scheduled for elective surgery under general anaesthesia. * age: one eight years old. * asa i and ii only. * patients with normal cardiorespiratory function. exclusion criteria: * children undergoing dental surgeries in which nasal intubation is needed. * patients who suffered from quick drops in oxygen saturation more rapidly than healthy children due to different reasons such as: respiratory and pulmonary diseases, active or recent upper respiratory tract infection, syndromes with cardiopulmonary pathologies, cardiac anomalies, anaemia, depressed respiratory effort, ventilation/perfusion imbalance, obstructive sleep apnoea (osa), and airway obstruction. * patients reported with nasal obstruction. * patients with grades of laryngoscopic view (cormack lahane) greater than ii, which indicates upper airway obstruction.

Keywords: apnoeic oxygenation airway management oxygen insufflation paediatric general anaesthesia
investigating the clinical utility of the mds

Conditions: Skin Lesion; Melanoma; Moles

Summary: the purpose of this study is to establish the clinical utility of the melanoma detection system (mds).

the purpose of this study is to establish the clinical utility of the mds while continuing to evaluate the safety and performance of the mds in patients with skin lesions who are referred to secondary care clinics for evaluation, whose lesions (moles) are suspicious for melanoma.

Eligibility criteria:
inclusion criteria: 1. lesion has one or more of the abcde features and is recommended for excision. 2. lesion has at least 1 cm of skin around it that is accessible to the mds. 3. patient is at least 18 years old. 4. patient is capable of giving written informed consent. 5. lesion is scheduled for primary excision. exclusion criteria: 1. lesion is less than one centimetre from the eyes. 2. lesion is on the palms of the hands or soles of the feet. 3. lesion is mucosal. 4. lesion is ulcerated. 5. patient is pregnant. 6. low patient study procedure compliance. 7. patient who is mentally or physically unable to comply with all aspects of the study. 8. patient is undergoing chemotherapy. 9. patient has known sensitivity to fluorescent dyes. 10. ink marking on or adjacent to lesion. 11. lesions larger than 20mm or too large to allow imaging.
pediatric population screening for type 1 diabetes and familial hypercholesterolemia in lower saxony, germany

Conditions: Type 1 Diabetes; Familial Hypercholesterolemia

Summary: this is a pilot/ feasibility study for a population-based screening in all children 2 to 6 years in lower saxony, germany during the compulsory (u7 (from the age of 2) u7a, u8, u9) routine check-ups and any voluntary visits to the pediatricians office.

the fr1dolin-study will be presented to the parents of ca. 320,000 children living in lower saxony, germany. the recruitment of subjects, collection of written consent, the capillary blood sample and the screening questionnaire will be done by the registered pediatricians in their local medical practices. after study enrolment 200 µl of capillary blood are be taken from the subject and are sent pseudo-anonymized to the lab. ldl-c and the diabetes-associated antibodies are identified. based on the results a second blood sample will be required. in case of pre-type-1 diabetes or signs for a familial hypercholesterolemia the pediatrician will be informed. he will contact the parents and discuss the further procedure in cooperation with the study center. in case of a positive result by measuring diabetes-related antibodies and ldl-c the goal of this trial is to advise and educate the families appropriate and to treat them if necessary. in addition families should have the possibility to participate in prevention trials. all data will be registered in a study database. follow-up pre-type 1 diabetes: during the first year, follow-up will be performed after 6 and 12 months and thereafter annually until the age of 12 years or up to 6 months after the clinical onset of type 1 diabetes. follow-up familial hypercholesterolemia: during the first year, follow-up will be performed after 6 and 12 months and thereafter annually until the age of 12 years.

Eligibility criteria:
inclusion criteria: * children living in lower saxony (primary residence) * age between 2 and 6 years (both included) * written consent by at least one parent / legal representative * willingness to deliver 200 µl of capillary blood * willingness to complete a questionnaire * willingness to participate to the follow-up visits exclusion criteria: • none
effect of neoadjuvant anti-pd-1 immunotherapy on perioperative analgesia and postoperative delirium

Conditions: Immunotherapy; Analgesia; NSCLC; Delirium

Summary: to observe the effect of preoperative anti-pd-1 monotherapy combined with chemotherapy on patients' perioperative pain and opioid analgesia, and evaluate its effect on the incidence and severity of patients' postoperative delirium.

in this study, the investigators intend to select patients with resectable nsclc treated with immuno-neoadjuvant therapy in combination with chemotherapy, systematically observe the effect of preoperative anti-pd-1 monotherapy on patients' perioperative pain and opioid analgesia, and evaluate its effect on the incidence and severity of patients' postoperative delirium, in order to provide a clinical basis for the perioperative management of patients treated with immuno-neoadjuvant therapy and promote their postoperative recovery.

Eligibility criteria:
inclusion criteria: * histologically confirmed stage ii or stage iiia non-small cell lung cancer (nsclc) and meet the requirements for r0 resection; * american society of anesthesiologists (asa): i-iii, age ≥18 years, body mass index (bmi): 18.5-30; * normal function of coagulation and vital organs such as heart, lungs, kidney, and liver; * eligible to receive platinum-containing two-drug chemotherapy; * sign the informed consent form exclusion criteria * prior treatment of any kind for current lung cancer, including chemotherapy, radiation or targeted therapy; * preoperative opioid analgesia; * severe chronic or active infection requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection; * history of antipsychotic medication in the last 6 months; * preoperative mini-mental state examination (mmse) score \<23
unified airway model

Conditions: Chronic Rhinosinusitis (Diagnosis); Asthma

Summary: chronic rhinosinusitis (crs) impacts approximately 5% of canadians. crs patients suffer from a combination of symptoms that include facial pain, nasal obstruction, hyposmia and mucopurulence discharge. asthma may additionally worsen quality of life and many patients suffer from both conditions. the unified airway model illustrates a link between both conditions as tissue from the middle ear to the sinus cavity to the lungs function as one unit. despite evidence for the unified airway model in the setting of crs and asthma, there are no studies to our knowledge that have evaluated the microbiome (the resident microbes and their genetic expressions that affect disease) of the upper and lower airways in this patient population. determining the microbiome of the upper and lower airways in patients suffering from crs and asthma will further support the unified airway model but more importantly, will help contribute to understanding the pathophysiology of this inflammatory process and may help guide future management.


Eligibility criteria:
inclusion criteria: * 19 years or older * able to speak and understand english * diagnosed with chronic rhinosinusitis with or without asthma and copd or with a sinonasal tumor * undergoing sinus surgery in st paul's hospital exclusion criteria: * oral antibiotics in the past month prior to surgery; * immunocompromised; * prior lung transplants; * known sinonasal or bronchial tumors, current or previous; * smoking; * known bleeding disorders: * deemed unfit by the rhinologists/respirologist for bronchoscopy.
a study to evaluate cjc 1295 in hiv patients with visceral obesity

Conditions: Obesity; HIV Infections

Summary: this is a multicenter, randomized, placebo-controlled, double-blind, phase 2 study. patients will be treated for a total of 12 weeks. there will be a 6 week follow-up period after the treatment period ends. patients will be randomly assigned to low dose cjc 1295, high dose cjc 1295 or placebo. the objective is to assess and compare the efficacy, pharmacokinetics, safety, and tolerability of cjc 1295 in patients with human immunodeficiency virus (hiv) associated visceral obesity.


Eligibility criteria:
inclusion criteria: * age 18-65 on stable antiviral regimen * documented hiv infection * hiv associated visceral obesity * body mass index (bmi) \> 24 and \< 30 kg/m2 exclusion criteria: * diabetes * use of growth hormone (gh) or other gh secretagogues * use of systemic glucocorticoids, * use of megestrol acetate or other appetite stimulants, * use of general anorexigenic or weight-reducing agents, or * use of androgens, other than testosterone replacement therapy for male hypogonadism at physiological doses and on a stable regimen for at least 6 months prior to randomization.

Keywords: treatment experienced hiv visceral obesity
comparison of effectiveness between active release technique and hold relax technique in patients with piriformis syndrome

Conditions: Piriformis Syndrome

Summary: this study is a randomized controlled trial and the purpose of this study is to compare the effects between active release technique and hold relax technique in patients with piriformis syndrome.

the purpose of this study is to compare the effects between active release technique and hold relax technique in patients with piriformis syndrome pain, range of motion, and functional disability, in adults (age: 25-55 years) 1. numeric pain rating scale 2. goniometer 3. oswestry disability questionairre data will be collected before and after the intervention protocol for each participant. data collection procedure: participants of interest would be approached and explained about the research. informed written consent will be taken. pre and post-intervention scores will be recorded.

Eligibility criteria:
inclusion criteria: * gender: both male and female * individuals aged 25-55 years * tenderness to palpation over sciatic foramen * positive fair test. exclusion criteria : * history of hip, pelvic, or femoral fractures. * malignancies. * avascular necrosis of femoral head. * inflammatory conditions (e.g. rheumatoid arthritis)
benefit of adding chemotherapy for advance nasopharyngeal carcinoma (t1-4n2-3m0)

Conditions: Nasopharyngeal Neoplasms; Carcinoma, Squamous Cell

Summary: to test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.


Eligibility criteria:
inclusion criteria: * undifferentiated or non-keratinizing carcinoma * tumor staged as n2-3 * no evidence of distant metastasis m0 * performance status:0-2 * marrow: wbc \>= 4 and platelet \>= 100 * renal: creatinine clearance \>= 60 * informed consent exclusion criteria: * who type i squamous cell carcinoma or adenocarcinoma * age \>= 70 * palliative intent or tumor extent mandating ap opposing facio-cervical fields * prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years * previous radiotherapy (except non-melanomatous skin cancers outside the intended rt treatment volume * previous chemotherapy * patient is pregnant or lactating

Keywords: nasopharyngeal carcinoma t1-4n2-3m0
trans gerd: efficacy and tolerability of esomeprazol in patients under ordinary medical care conditions

Conditions: Gastrointestinal Diseases

Summary: under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e. general practitioners and internists) are asked to document relevant data related to esomeprazole therapy in patients with gastrointestinal disorders. patients with acid associated gastrointestinal symptoms can be included.


Eligibility criteria:
inclusion criteria: * patients with gastrointestinal disorders and patients with acid associated gastrointestinal symptoms treated with esomeprazole. exclusion criteria: * limitiations; possible risks; warnings; contraindications mentioned in the spc.

Keywords: gastrointestinal disorder acid associated gastrointestinal symptoms. esomeprazole therapy in patients with gastrointestinal disorders patients with acid associated gastrointestinal symptoms